*Molecular Basis of Breast Cancer Flashcards

1
Q

What proportion of all cancers do breast cancers make up ?

A

10%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What proportion of breast cancers are familial ?

A

5-10%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Name the main genetic defects associated with breast cancer.

A

BRCA1 and BRCA2

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Identify the main features of genetic inheritance of BRCA1 mutations.

A
  • Autosomal Dominant
  • Increases lifetime risk to 50-80%, which means it’s not full penetrant (some are just carriers, i.e. this mutation is just a predisposition to breast cancer)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Identify any other cancers BRCA1 is associated with.

A

Also increases ovarian risk to 40-50%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

How may we test for BRCA1 gene defect ?

A

• Sequencing

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Where in the BRCA1 gene may defects occur ? What is the result of these defects ?

A
  • Mutations occur throughout gene
  • Over 650 different mutations identified
  • Most result in truncated protein (which may result in truncation of part of protein which normally binds to RAD51 (which assists in DNA repair) and/or part of the protein which is responsible for transcriptional activation)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Why do inherited defects in BRCA1 predispose to cancer?

A

♦ Why BRCA1 defects are problematic:

  • Tumor Supressor Gene
  • Overall, caretaker gene. Upon DNA damage, BRCA1 relocalises to sites of damage. Recognises that there is a DNA DS break, and brings with it some proteins that are able to digest away some of the bases to leave an exposed single strand (then BRCA2 takes over)

♦ Why inheriting a defect is problematic:
Two hit hypothesis: Both copies of tumour suppressor gene disrupted in tumour. May arise in both copies of the gene in the same cell by chance (rare and sporadic) or because patient has inherited one defective copy of the gene already. In this situation only need one further mutation to occur by chance and tumour will arise. Inheritance of the mutation therefore predisposes to disease.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Where in the BRCA2 gene may defects occur ? What is the result of these defects ?

A
  • More than 400 mutations reported
  • Large gene- likely to have ‘Variants of unknown significance’- missense, intronic and small in frame deletions or insertions
  • Most result in truncated protein (which may result in truncation of part of protein which normally binds to RAD51 (which assists in DNA repair))
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Identify any other cancers BRCA2 is associated with.

A

Increases rick of prostate cancer in males (as well as breast cancer in males)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Define Founder Effect, and explain how it links to genes for breast cancer.

A

An unusually high frequency of a gene in a particular population derived from a small set of unrepresentative ancestors.

BRCA2 has high frequency in Ashkenazi Jewish community (due to inbreeding)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Why do inherited defects in BRCA2 predispose to cancer?

A

♦ Why BRCA2 defects are problematic:

  • BRCA2 disruption associated with spontaneous chromosomal instability, including aberrations such as chromatid breaks, triradial chromosomes and quadriradial chromosomes
  • Overall, (after BRCA1 fulfills its role) BRCA2 binds to RAD51, and recruits it to sites of DNA damage. This then stimulates the start of homology directed repair.

♦ Why inheriting a defect is problematic:
Two hit hypothesis: Both copies of tumour suppressor gene disrupted in tumour. May arise in both copies of the gene in the same cell by chance (rare and sporadic) or because patient has inherited one defective copy of the gene already. In this situation only need one further mutation to occur by chance and tumour will arise. Inheritance of the mutation therefore predisposes to disease.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Describe the process of homology directed repair of DNA double strand breaks by BRCA2.

A

“Template-directed repair. It works during the most critical point of cell replication—after DNA is copied but before it divides. With the two chromatids still held together by a cohesion complex, HRR takes advantage of having a full copy of DNA present and proximally accessible. This enables HRR to find a large area of homology (usually on a sister chromatid) and use it as a template to reconstruct the damaged DNA strand”

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

To what extent do BRCA1 and 2 participate in the same pathway ?

A

They do.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Why is the breast specifically affected by mutations in BRCA1/2 ?

A

1) Tissue specific effects that promote tumourigenesis.
2) Tissue specific expression of BRCA genes.
3) Responsiveness to hormones, especially oestrogen. Metabolism of oestrogen may result in free radicals to increase DNA damage (can set cells off on path to cancer)
4) Bi-allelic loss of BRCA usually detrimental to DNA repair (chromosome instability). Must be compensating mutations that allows BRCA-/- cells to grow out and evolve into full blown tumours.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Which genetic mutation is associated with male breast cancer ?

A

BRCA2 mutation

17
Q

Are the genes involved in familial breast cancer also the genes involved in sporadic breast cancer ?

A

Unlike colon cancer and APC story the same genes do not seem to be mutated frequently in sporadic breast/ovarian cancer.

18
Q

Identify factors to consider in referral for genetic counselling for breast cancer.

A

Factors to consider for referral to pre-symptomatic genetic testing/counselling:

  • Number of family members affected
  • What generations?
  • Age of onset (familial generally younger than sporadic)
  • Ethnic background (e.g. Ashkenazi higher susceptibility)
  • Breast cancer susceptibility genes have low penetrance (so not everyone who has mutation will have cancer)
  • Polygenic disease (so just because didn’t find mutations in BRCA1 or 2 doesn’t mean no genetic prediposition)
19
Q

If mutations in BRCA1/2 were found, how can the risk of breast cancer be managed ?

A

1) More regular MRI or mammography:
(MRI detected 2X tumours compared to mammography, BUT higher false positive rate)

2) Prophylactic mastectomy (reduces risk of breast cancer) or oophorectomy (reduces risk of breast and ovarian cancer)

20
Q

What are the implications of the presence of BRCA1/2 mutations in breast cancer, on treatment for breast cancer ?

A

To treat breast cancer, need to kill tumor cells but leave normal cells unaffected. If treat cells with DNA damaging agent, which is causing DNA DS breaks, then tumor cells (lacking both copies) are dying much more prevalently than wiltype or heterozygous. Can we exploit BRCA-/- cells sensitivity to DNA damage as a way of killing the tumours?

21
Q

Describe any treatment used for familial breast cancer, explaining the basis behind its functioning.

A

• Synthetic lethality: two genetic mutations are independently compatible with life BUT together cause mortality.

PARP (Poly (ADP-ribose) polymerase) repairs SS DNA breaks through base excision repair.
BRCA1/2 repair DS DNA breaks through homologous recombination

If only one of these two pathways is defective (i.e. BRCA1/2 is defective while PARP is fine, or vice versa) then cells are viable (e.g. if PARP is defective then DNA SS break will be converted into DNA DS, and HR can address that). HOWEVER, if a cell has no working BRCA1 or 2 (e.g. in breast cancer) and then inhibit PARP, the cell unable to repair DNA damage, resulting in cell death.

HENCE, Olaparib (PARP inhibitor) used for BRCA tumours where patients have not responded to other chemotherapy (only in BRCA tumors because BRCA +/+ or +/- still have capability to undergo HR for DNA repair)

22
Q

Identify any major issues encountered by Olaparib as a treatment for breast cancer.

A

Resistance (group of cells which are initially genetically unstable and vulnerable to drug can become resistant over time to PARP inhibitor).

This occurs via reverse mutations:
BRCA2 protein produced by the relevant cells. BRCA-/- cells are deficient at DNA repair BUT can still do some albeit badly. Sometimes that repair results in a BRCA2 gene which has more function than the original cells so become resistant to drug (since cell became more stable and able to repair other DNA DS breaks).

23
Q

Identify risk factors for sporadic breast cancers.

A
  • Early menarche
  • Late menopause
  • First child after 30 years of age
24
Q

How may we determine most appropriate treatment for a sporadic breast cancer ?

A

Histopathology:

1) Stage and grade of the tumor influence prognosis, which may affect treatment options
2) The type of cells involves also matters: 10% are lobular, 90% are ductal (invasive tumours), which can either be luminal (majority) or basal-like. Molecular analysis helps divide into these categories and largely determines chemotherapy. Breast tumors can be positive for specific proteins, notably estrogen receptor, progesterone receptor, and HER2. May be positive for some (e.g. luminal tumors + for ER, +/- for other two), may be positive for all, may be triple negative (e.g. basal-like tumors). This classification also influences treatment.

25
Q

What proportion of breast cancers are ER positive ? HER2 positive ?

A
  • Around 60% ER Positive

* HER2/erbB2 over-expressed in 20-30% of breast cancers

26
Q

What is the significance of Estrogen Receptor in breast cancer ?

A
  • Estrogen receptor (in the nucleus), in absence of estrogen, unable to bind to its partners.
  • Its partners are transcription factors that allow the expression of particular genes
  • When estrogen comes along, it binds to receptor, which is then able to bind to other TFs and promote transcription of estrogen responsive genes (estrogen responsive genes can include those which drive proliferation)
27
Q

Identify any treatments targeting ER positive tumors. State the specific indications for this, and any side effects.

A

Hormone Therapy: tamoxifen

  • Prodrug
  • Antagonist of Oestrogen receptor (binds to it), prevents expression of genes which would otherwise be stimulated by oestrogen
  • Specific to ER (no effect in cell without ER)
  • Often used prophylactically after surgery for early stage breast cancer
  • Common side effect- hot flushes
28
Q

What is the significance of Epidermal Growth Factor Receptor 2 (HER2/erbB2) in breast cancer ?

A

-Overexpressed in breast cancer (gene amplification)
-Growth Factor Receptor on cell surface
-Tyrosine Kinase, so acts as a dimer and once activated following binding of GF, sends signal to nucleus
resulting in Transcription of genes which will drive cell proliferation

If overexpressed (e.g. in HER2 positive breast cancer), increased signaling, more cell proliferation

29
Q

Identify any treatments targeting HER2 positive tumors. State the specific indications for this, and any side effects.

A

Trastuzumab (Herceptin) (‘Humanised’ monoclonal antibody to HER2 )

  • Inhibits HER2 (binds to HER2+ cancer cell) and prevents signalling
  • Suppresses growth and angiogenesis
  • Cell mediated cytotoxicity (Herceptin signals to body’s immune system to target cancer)
30
Q

What does it mean that Herceptin is a humanised monoclonal antibody ?

A

Raise monoclonal antibody in mouse but can’t use it directly in man because mouse antibodies would be recognized as ‘foreign’. Therefore have to ‘humanize’ it such that the mouse part recognizes the antigen and the human part protects it from the host immune system.

31
Q

Identify any other treatment options for breast cancers which are triple negative for ER, PR, and HER2.

A
  • Many tumours are aneuploid, so begs question is mitotic checkpoint working properly?
  • Can exploit weaknesses in that checkpoing by treating cells with Docetaxel (Taxotere).
32
Q

Describe how Docetaxel (Taxotere) works.

A

Docetaxel (Taxotere)

-Stabilises microtubules, resulting in aberrant, multipolar spindles (resulting in mitotic catastrophe, so chromosomes cannot segregate, resulting in apoptosis)